```
umber (Lnnn).
ENTER NAME OR (END):lradcox2/l
L# LIST L1-L94 HAS BEEN SAVED AS 'LRADCOX2/L'

=> d his

     (FILE 'HOME' ENTERED AT 17:26:34 ON 05 JUN 2003)

     FILE 'REGISTRY' ENTERED AT 17:26:59 ON 05 JUN 2003
L1             1 S ROFECOXIB
L2             1 S CELECOXIB/CN

     FILE 'CAPLUS' ENTERED AT 17:27:45 ON 05 JUN 2003
L3           383 S L1/USES
L4          1409 S (RADIATION OR RADIO?) (1S) ((SIDE OR ADVERSE OR UNDESIRED OR
L5         89355 S FATIGUE OR DIARRHEA OR (RECTAL BLEEDING) OR PROCTITIS OR SIGM
L6         22148 S DERMATITIS OR (LARGE BOWEL IRRITATION) OR (SMALL BOWEL IRRITA
L7        109277 S L5 OR L6
L8           106 S L4 AND L7
L9             1 S L3 AND L8
L10           28 S L3 AND L7
L11        17088 S (L5 (1S) TREAT?) OR (TREAT? (1S)L6)
L12           13 S L11 AND L3
L13        11975 S DERMATITIS
L14            2 S  (LARGE BOWEL IRRITATION) OR (SMALL BOWEL IRRITATION) OR (BOW
L15        10189 S NAUSEA OR VOMITING
L16         1100 S  (LARGE BOWEL IRRITATION) OR (SMALL BOWEL IRRITATION) OR (BOW
L17        74418 S FATIGUE
L18        13344 S  DIARRHEA
L19        89355 S FATIGUE OR DIARRHEA OR (RECTAL BLEEDING) OR PROCTITIS OR SIGM
L20           53 S  (RECTAL BLEEDING)
L21           54 S  (RECTAL (2A) BLEEDING)
L22           57 S  (RECT? (2A) BLEEDING)
L23           95 S PROCTITIS
L24            3 S  SIGMOIDITIS
L25          228 S (URINARY FREQUENCY)
L26          573 S  PROSTATITIS
L27         1009 S  CYSTITIS
L28            1 S L27 AND L3
L29            2 S L26 AND L3
L30            0 S L25 AND L3
L31            1 S L24 AND L3
L32            0 S L23 AND L3
L33            0 S L22 AND L3
L34            0 S L21 AND L3
L35            0 S L20 AND L3
L36            8 S L19 AND L3
L37            6 S L18 AND L3
L38            2 S L17 AND L3
L39            6 S L16 AND L3
L40            7 S L15 AND L3
L41            0 S L14 AND L3
L42           16 S L13 AND L3
L43           13 S L12 AND L3
L44           13 S L11 AND L3
L45           28 S L10 AND L3
L46          472 S L2/USES
L47           13 S L10 AND L46
L48           14 S L11 AND L46
L49            9 S L12 AND L46
L50            9 S L13 AND L46
L51            0 S L14 AND L46
L52            2 S L15 AND L46
L53            6 S L16 AND L46
```

```
L54             3 S L17 AND L46
L55             8 S L18 AND L46
L56            11 S L19 AND L46
L57             0 S L20 AND L46
L58             0 S L21 AND L46
L59             0 S L22 AND L46
L60             0 S L23 AND L46
L61             1 S L24 AND L46
L62             0 S L25 AND L46
L63             2 S L26 AND L46
L64             1 S L27 AND L46
L65             1 S L28 AND L46
L66             2 S L29 AND L46
L67           487 S L28-L64
L68           305 S L67 AND TREAT?
L69            30 S L28-L42
L70            23 S L50-L64
L71            38 S L69 OR L70

     FILE 'USPATFULL' ENTERED AT 18:14:13 ON 05 JUN 2003
L72           473 S CELECOXIB
L73           314 S ROFECOXIB
L74           124 S L1
L75           135 S L2
L76           517 S L72 OR L75
L77           373 S L73 OR L74
L78         80230 S L13-L27
L79          9477 S L13
L80          8831 S L15
L81          3121 S L16
L82         57401 S L17
L83          7764 S L18
L84           194 S L22
L85           715 S L23
L86            12 S L24
L87           188 S L25
L88           966 S L26
L89          1500 S L27
L90         18843 S (L79-89) (1S) TREAT?
L91           216 S L90 AND L76
L92           161 S L90 AND L77
L93             2 S L90 (3S) L77
L94             7 S L90 (3S) L76
                  SAVE ALL LRADCOX2/L

=>
```

AN 2001:167798 CAPLUS
DN 134:202695
TI Method for treating or preventing chronic **prostatitis** or chronic pelvic pain syndrome with COX-2 selective inhibitor
IN Nickel, Curtis J.; Stoner, Elizabeth; Waldstreicher, Joanne; Pontari, Michel A.
PA Merck & Co., Inc., USA; Temple University - of the Commonwealth System of Higher Education
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-18
CC 1-7 (Pharmacology)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001015687	A1	20010308	WO 2000-US23100	20000824
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6403640	B1	20020611	US 2000-644998	20000824
EP 1212051	A1	20020612	EP 2000-961351	20000824
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI US 1999-151126P	P	19990827		
WO 2000-US23100	W	20000824		

AB The use of a COX-2 selective inhibitor for the treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome is disclosed.

ST COX2 inhibitor **prostatitis** chronic pelvic pain syndrome; cyclooxygenase 2 inhibitor treatment chronic **prostatitis**

IT Prostate-specific antigen
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates, in combination with COX-2 inhibitor; COX-2 selective inhibitor for treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)

IT Analgesics
Antibiotics
Cholinergic antagonists
(in combination with COX-2 inhibitor; COX-2 selective inhibitor for treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)

IT Body, anatomical
(pelvis, chronic pelvic pain syndrome; COX-2 selective inhibitor for treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)

IT Prostate gland
(**prostatitis**; COX-2 selective inhibitor for treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)

IT Drug delivery systems
(topical, urinary analgesics, in combination with COX-2 inhibitor; COX-2 selective inhibitor for treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)

IT Adrenoceptor antagonists
(.alpha.1-, in combination with COX-2 inhibitor; COX-2 selective inhibitor for treatment or prevention of chronic **prostatitis**

or chronic pelvic pain syndrome)

IT 51803-78-2, Nimesulide 71125-38-7, Meloxicam 80937-31-1, Flosulide
88149-94-4, DuP 697 123653-11-2, NS 398 **162011-90-7**, Rofecoxib
162054-19-5, SC-58125 169590-42-5, Celecoxib 179382-91-3, RS 57067
181695-72-7, Valdecoxib 198470-84-7, Parecoxib 202409-33-4, MK-663
RL: THU (Therapeutic use); BIOL (Biological study); **USES (Uses)**
(COX-2 selective inhibitor for treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)

IT 39391-18-9
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(cyclooxygenase-2, selective inhibitors; COX-2 selective inhibitor for treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)

IT 9081-34-9, 5.alpha.-Reductase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, in combination with COX-2 inhibitor; COX-2 selective inhibitor for treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Aotsuka; US 6136831 A 2000 CAPLUS
(2) Canale; Andrologia 1993, V25(3), P163 MEDLINE
(3) Canale; Drugs 1993, Suppl 1, P147
(4) Grelan Pharmaceutical Co Ltd; WO 9846594 A1 1998 CAPLUS
(5) Guess; US 6054455 A 2000 CAPLUS
(6) Melis; Minerva Ginecologica 1997, V49(9), P409 MEDLINE
(7) Venturini; Cephalalgia

CAPLUS COPYRIGHT 2003 ACS
AN 2001:904209 CAPLUS
DN 136:31724
TI Heterocycle derivatives and methods of use
IN Peterson, Johnny W.; Gessell-Lee, Deborah L.; Saini, Shamsher S.
PA The University of Texas System, USA
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07H019-20
CC 1-12 (Pharmacology)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001094369	A2	20011213	WO 2001-US16190	20010519

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002032228	A1	20020314	US 2001-860652	20010519
US 20020188016	A9	20021212		
PRAI US 2000-210412P	P	20000608		

OS MARPAT 136:31724
AB The present invention provides methods for treating intestinal fluid loss, whooping cough, anthrax, and conditions assocd. with smooth muscle contraction. The present invention also provides methods for inhibiting adenylate cyclase in vivo and in vitro.
ST heterocycle deriv adenylate cyclase inhibition **diarrhea**; intestinal fluid loss treatment heterocycle deriv; smooth muscle contraction inhibition heterocycle deriv; whooping cough treatment heterocycle deriv
IT Animal cell
(adenylate cyclase-contg.; heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)
IT Prostaglandins
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(analogs; heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)
IT Bacillus anthracis
(anthrax from; heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)
IT Heterocyclic compounds
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(arom., di-Ph; heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)
IT ADP ribosylation
(by pathogenic organisms; heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)
IT Toxins

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(cholera, intestinal fluid loss stimulation by; heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT Intestine, disease
(fluid loss; heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT Antidiarrheals
Pertussis
(heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT Heterocyclic compounds
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT Aromatic compounds
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterocyclic, di-Ph; heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT Intestine, disease
(infection, fluid loss assocd. with pathogenic; heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT Pathogen
(intestinal fluid loss assocd. with; heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT Body fluid
(loss; heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT Muscle relaxants
(smooth; heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT 56-65-5, 5'-ATP, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cAMP formation from; heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT 363-24-6, PGE2
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(cAMP formation stimulation by and reaction with L-histidine; heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax)

IT 60-92-4, CAMP
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(formation; heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT 9012-42-4, Adenylate cyclase
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT 380153-74-2 380153-75-3
RL: DMA (Drug mechanism of action); FMU (Formation, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

IT 53-86-1, Indomethacin 71-00-1, L-Histidine, biological studies 288-32-4, Imidazole, biological studies 443-48-1, Metronidazole 88149-94-4 **162011-90-7** 169590-42-5 188817-13-2
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); **USES (Uses)**
(heterocycle derivs. for inhibiting adenylate cyclase and methods of use for treating intestinal fluid loss and whooping cough and anthrax and conditions assocd. with smooth muscle contraction)

L10 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2003 ACS
AN 2001:935403 CAPLUS
DN 136:50368
TI COX-2 inhibitors and the prevention of the side effects of radiation therapy
IN Herbst, Arthur L.; Weichselbaum, Ralph
PA USA
SO PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-415
ICS A61K031-34
CC 8-10 (Radiation Biochemistry)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001097806	A1	20011227	WO 2001-US19593	20010620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002035139	A1	20020321	US 2001-884466	20010620
EP 1309328	A1	20030514	EP 2001-950340	20010620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI US 2000-212685P	P	20000620		
WO 2001-US19593	W	20010620		

AB A generalized method is disclosed for reducing the deleterious side effects of radiotherapy in subjects undergoing radiotherapy for the treatment of cancer. The method is the administration to a subject of a side-effect reducing amt. of one or more selective cyclooxygenase-2 (COX-2) inhibitor.

ST cyclooxygenase 2 inhibitor radiotherapy toxic side effect

IT **Dermatitis**
Diarrhea
Digestive tract
Fatigue, biological
Radiotherapy
Urinary tr

L12 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2003 ACS
AN 2001:167798 CAPLUS
DN 134:202695
TI Method for **treating** or preventing chronic **prostatitis** or chronic pelvic pain syndrome with COX-2 selective inhibitor
IN Nickel, Curtis J.; Stoner, Elizabeth; Waldstreicher, Joanne; Pontari, Michel A.
PA Merck & Co., Inc., USA; Temple University - of the Commonwealth System of Higher Education
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-18
CC 1-7 (Pharmacology)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001015687	A1	20010308	WO 2000-US23100	20000824
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6403640	B1	20020611	US 2000-644998	20000824
EP 1212051	A1	20020612	EP 2000-961351	20000824
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI US 1999-151126P	P	19990827		
WO 2000-US23100	W	20000824		

AB The use of a COX-2 selective inhibitor for the **treatment** or prevention of chronic **prostatitis** or chronic pelvic pain syndrome is disclosed.
ST COX2 inhibitor **prostatitis** chronic pelvic pain syndrome; cyclooxygenase 2 inhibitor **treatment** chronic **prostatitis**
IT Prostate-specific antigen
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates, in combination with COX-2 inhibitor; COX-2 selective inhibitor for **treatment** or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)
IT Analgesics
Antibiotics
Cholinergic antagonists
(in combination with COX-2 inhibitor; COX-2 selective inhibitor for **treatment** or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)
IT Body, anatomical
(pelvis, chronic pelvic pain syndrome; COX-2 selective inhibitor for **treatment** or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)
IT Prostate gland
(**prostatitis**; COX-2 selective inhibitor for **treatment** or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)
IT Drug delivery systems
(topical, urinary analgesics, in combination with COX-2 inhibitor; COX-2 selective inhibitor for **treatment** or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)
IT Adrenoceptor antagonists

(.alpha.1-, in combination with COX-2 inhibitor; COX-2 selective inhibitor for **treatment** or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)

IT 51803-78-2, Nimesulide 71125-38-7, Meloxicam 80937-31-1, Flosulide 88149-94-4, DuP 697 123653-11-2, NS 398 **162011-90-7**, Rofecoxib 162054-19-5, SC-58125 169590-42-5, Celecoxib 179382-91-3, RS 57067 181695-72-7, Valdecoxib 198470-84-7, Parecoxib 202409-33-4, MK-663
RL: THU (Therapeutic use); BIOL (Biological study); **USES (Uses)**
(COX-2 selective inhibitor for **treatment** or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)

IT 39391-18-9
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(cyclooxygenase-2, selective inhibitors; COX-2 selective inhibitor for **treatment** or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)

IT 9081-34-9, 5.alpha.-Reductase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, in combination with COX-2 inhibitor; COX-2 selective inhibitor for **treatment** or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Aotsuka; US 6136831 A 2000 CAPLUS
(2) Canale; Andrologia 1993, V25(3), P163 MEDLINE
(3) Canale; Drugs 1993, Suppl 1, P147
(4) Grelan Pharmaceutical Co Ltd; WO 9846594 A1 1998 CAPLUS
(5) Guess; US 6054455 A 2000 CAPLUS
(6) Melis; Minerva Ginecologica 1997, V49(9), P409 MEDLINE
(7) Venturini; Cephalalgia 1997, V17/20(29-30)

=>

L71 ANSWER 38 OF 38 CAPLUS COPYRIGHT 2003 ACS

IT **Dermatitis**

(contact; compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

IT 32222-06-3, Calcitriol 59865-13-3, Cyclosporin a 60940-34-3, Ebselen 71125-38-7, Meloxicam 79217-60-0, Cyclosporin 80937-31-1, Flosulide 85259-71-8, BAY 0-8276 88149-94-4, Dup 697 93014-16-5 101910-24-1, PF-5901 110501-66-1, TMK-688 111908-95-3, SK&F-104493 117423-74-2, LY 223982 117423-95-7, LY 213024 117690-79-6, LY-255283 118414-82-7, MK-886 119261-58-4, TEI 1338 120072-59-5, SC-41930 123653-11-2, NS-398 128253-31-6, Bay-x-1005 130211-75-5, T-757 132734-43-1, LY 233569 133430-69-0, ETH-615 134578-96-4, ONO LB457 135199-82-5, LY 264086 135893-33-3, PF 10042 136326-31-3, WAY 121006 141059-52-1, SC-51146 141748-00-7, RP 69698 141835-49-6, RG 14893 142422-79-5, RP 66153 146461-98-5, SM 15178 147030-01-1, MK-591 147398-01-4, CGS-25019C 147432-77-7, Ontazolast 150399-22-7, SB-201993 153034-77-6, LY 292728 153633-01-3, SC-53228 154413-61-3, SB-209247 158081-99-3, Pfizer 105696 161172-51-6, LY-293111 162011-83-8 **162011-90-7** 162153-46-0, SC 52798 169590-41-4 **169590-42-5** 177660-77-4 177660-80-9 177660-92-3 180208-37-1, SB-201146 181695-72-7 185344-51-8 185344-55-2 186912-85-6, ONO-LB-448 186912-92-5, RP 66364 186912-94-7, SC-50505 195061-34-8 195215-25-9, BPC 15 195215-47-5, MNX 160 195215-53-3, S 2474 195215-55-5, SR 2566

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);

USES (Uses)

(compns. comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection)

ACCESSION NUMBER: 1997:557660 CAPLUS

DOCUMENT NUMBER: 127:239120

TITLE: Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist for reducing transplant rejection

INVENTOR(S): Gregory, Susan A.; Isakson, Peter C.; Anderson, Gary

PATENT ASSIGNEE(S): G.D. Searle & Co., USA; Gregory, Susan A.; Isakson, Peter C.; Anderson, Gary

SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9729775	A1	19970821	WO 1997-US1422	19970211
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2246356	AA	19970821	CA 1997-2246356	19970211
AU 9722500	A1	19970902	AU 1997-22500	19970211
EP 880362	A1	19981202	EP 1997-905663	19970211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2000505445	T2	20000509	JP 1997-529359	19970211
US 6172096	B1	20010109	US 1998-75633	19980511

PRIORITY APPLN. INFO.: US 1996-600580 A1 19960213
WO 1997-US1422 W 19970211

OTHER SOURCE(S): MARPAT 127:239120

=>

L71 ANSWER 37 OF 38 CAPLUS COPYRIGHT 2003 ACS

IT **Dermatitis**
(contact; immunosuppressive combinations contg. cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)

IT 71125-38-7, Meloxicam 80937-31-1, Flosulide 88149-94-4, DuP 697 123653-11-2, NS-398 162011-83-8 169590-41-4 **169590-42-5** 170569-86-5 177660-77-4 177660-80-9 177660-88-7 181695-76-1 185344-61-0 194997-65-4 194997-66-5 194997-67-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(cyclooxygenase-2 inhibitor; immunosuppressive combinations contg. cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)

IT **162011-90-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(immunosuppressive combinations contg. cyclooxygenase-2 inhibitor and LTA4 hydrolase inhibitor)

ACCESSION NUMBER: 1997:562995 CAPLUS
DOCUMENT NUMBER: 127:225303
TITLE: Immunosuppressive combinations containing a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
INVENTOR(S): Gregory, Susan A.; Isakson, Peter C.; Anderson, Gary
PATENT ASSIGNEE(S): G.D. Searle & Co., USA; Gregory, Susan A.; Isakson, Peter C.; Anderson, Gary
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9729774	A1	19970821	WO 1997-US1421	19970211
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2246336	AA	19970821	CA 1997-2246336	19970211
AU 9719525	A1	19970902	AU 1997-19525	19970211
EP 880363	A1	19981202	EP 1997-907545	19970211
EP 880363	B1	20020911		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2001506574	T2	20010522	JP 1997-529358	19970211
AT 223732	E	20020915	AT 1997-907545	19970211
ES 2183140	T3	20030316	ES 1997-907545	19970211
US 6407140	B1	20020618	US 2000-489311	20000121
US 2003004191	A1	20030102	US 2002-137231	20020502

PRIORITY APPLN. INFO.: US 1996-600655 A1 19960213
WO 1997-US1421 W 19970211
US 2000-489311 A3 20000121

OTHER SOURCE(S): MARPAT 127:225303

L71 ANSWER 38 OF 38 CAPLUS COPYRIGHT 2003 ACS

L71 ANSWER 32 OF 38 CAPLUS COPYRIGHT 2003 ACS
IT Anti-inflammatory agents
Dermatitis
UV B radiation
(cyclooxygenase 2 inhibitor Celecoxib suppression of UVB-mediated cutaneous inflammation)
IT **169590-42-5**, Celecoxib
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(cyclooxygenase 2 inhibitor Celecoxib suppression of UVB-mediated cutaneous inflammation)

ACCESSION NUMBER: 2000:757695 CAPLUS
DOCUMENT NUMBER: 134:65940
TITLE: Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation
AUTHOR(S): Wilgus, Traci A.; Ross, Mary S.; Parrett, Michelle L.; Oberyszyn, Tatiana M.
CORPORATE SOURCE: Department of Molecular Virology, Immunology and Medical Genetics, The College of Medicine, The Ohio State University, Columbus, OH, 43210, USA
SOURCE: Prostaglandins & Other Lipid Mediators (2000), 62(4), 367-384
CODEN: POLMFL; ISSN: 1098-8823
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 82 THERE ARE 82 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 31 OF 38 CAPLUS COPYRIGHT 2003 ACS
TI Method for treating or preventing chronic **prostatitis** or chronic pelvic pain syndrome with COX-2 selective inhibitor
AB The use of a COX-2 selective inhibitor for the treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome is disclosed.
ST COX2 inhibitor **prostatitis** chronic pelvic pain syndrome; cyclooxygenase 2 inhibitor treatment chronic **prostatitis**
IT Prostate-specific antigen
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates, in combination with COX-2 inhibitor; COX-2 selective inhibitor for treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)
IT Analgesics
Antibiotics
Cholinergic antagonists
(in combination with COX-2 inhibitor; COX-2 selective inhibitor for treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)
IT Body, anatomical
(pelvis, chronic pelvic pain syndrome; COX-2 selective inhibitor for treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)
IT Prostate gland
(**prostatitis**; COX-2 selective inhibitor for treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)
IT Drug delivery systems
(topical, urinary analgesics, in combination with COX-2 inhibitor; COX-2 selective inhibitor for treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)
IT Adrenoceptor antagonists
(.alpha.1-, in combination with COX-2 inhibitor; COX-2 selective inhibitor for treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)
IT 51803-78-2, Nimesulide 71125-38-7, Meloxicam 80937-31-1, Flosulide 88149-94-4, DuP 697 123653-11-2, NS 398 **162011-90-7**, Rofecoxib 162054-19-5, SC-58125 **169590-42-5**, Celecoxib 179382-91-3, RS 57067 181695-72-7, Valdecoxib 198470-84-7, Parecoxib 202409-33-4, MK-663
RL: THU (Therapeutic use); BIOL (Biological study); **USES (Uses)**
(COX-2 selective inhibitor for treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)
IT 39391-18-9
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(cyclooxygenase-2, selective inhibitors; COX-2 selective inhibitor for treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)
IT 9081-34-9, 5.alpha.-Reductase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, in combination with COX-2 inhibitor; COX-2 selective inhibitor for treatment or prevention of chronic **prostatitis** or chronic pelvic pain syndrome)
ACCESSION NUMBER: 2001:167798 CAPLUS
DOCUMENT NUMBER: 134:202695
TITLE: Method for treating or preventing chronic **prostatitis** or chronic pelvic pain syndrome with COX-2 selective inhibitor
INVENTOR(S): Nickel, Curtis J.; Stoner, Elizabeth; Waldstreicher, Joanne; Pontari, Michel A.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Temple University - of the Commonwealth System of Higher Education
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001015687	A1	20010308	WO 2000-US23100	20000824
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6403640	B1	20020611	US 2000-644998	20000824
EP 1212051	A1	20020612	EP 2000-961351	20000824
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: US 1999-151126P P 19990827
WO 2000-US23100 W 20000824
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 29 OF 38 CAPLUS COPYRIGHT 2003 ACS
IT Intestine, disease
(**irritable bowel** syndrome, constipation-predominant; cyclooxygenase-2 inhibitors for treatment of constipation)
IT 51803-78-2, Nimesulide 51803-78-2D, Nimesulide, derivs. 80937-31-1, Flosulide 80937-31-1D, Flosulide, derivs. 81098-60-4, Cisapride 123653-11-2, NS 398 123653-11-2D, NS 398, derivs. 158205-05-1, L-745337 158205-05-1D, L-745337, derivs. **162011-90-7**, Rofecoxib **162011-90-7D**, Rofecoxib, derivs. **169590-42-5**, Celecoxib **169590-42-5D**, Celecoxib, derivs. 180200-68-4, JTE-522 180200-68-4D, JTE-522, derivs. 181695-72-7, Valdecoxib 181695-72-7D, Valdecoxib, derivs. 183610-65-3 183610-65-3D, derivs. 189954-66-3 189954-66-3D, derivs. 198470-84-7, Parecoxib 198470-84-7D, Parecoxib, derivs. 202409-33-4, Etoricoxib 202409-33-4D, Etoricoxib, derivs. 220991-20-8D, derivs. 221148-46-5 221148-46-5D, derivs. 267235-56-3 267235-56-3D, derivs. 342651-37-0 342651-37-0D, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); **USES (Uses)**
(cyclooxygenase-2 inhibitors for treatment of constipation)

ACCESSION NUMBER: 2001:581693 CAPLUS
DOCUMENT NUMBER: 135:147439
TITLE: Use of cyclooxygenase-2 (COX-2) inhibitors for constipation
INVENTOR(S): Mangel, Allen Wayne; Naylor, Alan
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056555	A2	20010809	WO 2001-GB416	20010201
WO 2001056555	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1251839	A2	20021030	EP 2001-948935	20010201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003013717	A1	20030116	US 2002-182169	20020725

PRIORITY APPLN. INFO.: GB 2000-2312 A 20000201
WO 2001-GB416 W 2001

L71 ANSWER 28 OF 38 CAPLUS COPYRIGHT 2003 ACS

AB Cyclooxygenase (Cox)-2 expression and inhibition were investigated in a rabbit ileal loop model of Clostridium difficile colitis and **diarrhea**. Intestinal tissue stimulated with C. difficile toxin A showed up-regulation of Cox-2 expression in lamina propria macrophages and elevated prostaglandin levels. Toxin A-stimulated loops exhibited severe inflammation and increased secretory vol. Celecoxib, a specific Cox-2 inhibitor, significantly reduced toxin A-induced prostaglandin prodn. Furthermore, celecoxib (.gtoreq.0.02 mg/mL) blocked both histol. damage (mean histol. grade, 1.25 vs. 3.44 in rabbits receiving toxin A alone; P < .0005) and secretion (vol.:length ratio, 0.18 vs. 0.72 in those receiving toxin A alone; P = .002) in toxin A-stimulated loops in a dose-related manner. Thus, toxin A induced expression of Cox-2 in the host, and prostaglandins produced through Cox-2 were involved in the mediation of the increased secretion of electrolytes and water and the inflammatory response induced by toxin A.

IT Clostridium difficile
Diarrhea
Inflammation
(cyclooxygenase and prostaglandins in Clostridium difficile toxin A-induced secretion and inflammation in animal model)

IT **169590-42-5**, Celecoxib
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(cyclooxygenase and prostaglandins in Clostridium difficile toxin A-induced secretion and inflammation in animal model response to)

ACCESSION NUMBER: 2001:696264 CAPLUS
DOCUMENT NUMBER: 135:268592
TITLE: Role of inducible cyclooxygenase and prostaglandins in Clostridium difficile toxin A-induced secretion and inflammation in an animal model
AUTHOR(S): Alcantara, Cirle; Stenson, William F.; Steiner, Theodore S.; Guerrant, Richard L.
CORPORATE SOURCE: Division of Geographic Medicine, Department of Medicine, University of Virginia, Charlottesville, VA, 22908, USA
SOURCE: Journal of Infectious Diseases (2001), 184(5), 648-652
CODEN: JIDIAQ; ISSN: 0022-1899
PUBLISHER: University of Chicago Press
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PATENT.

L94 ANSWER 6 OF 7 USPATFULL

DETD As this study was continued, 35 patients with CD were being **treated** with RMAT. 37% (13/35) of the patients developed a serum sickness-like illness during the first 4-6 weeks of **treatment**. The patients experienced flu-like symptoms such as fever, chills, moderate to severe arthralgia, back pain, anorexia, and **fatigue** . These symptoms generally lasted for a full week and dissipated over the following 3 weeks. With each patient, a majority of symptoms stopped within the first month of **treatment**. It was also found that these symptoms responded well to Cox-2 inhibitors (**celecoxib** --200 mgm po qd) with no adverse effects or worsening of colitis noted during **treatment**. These observations suggest that the Cox-2 inhibitors may help in controlling the initial side effects of RMAT. It is also thought that this serum sickness may be a Jarisch-Herxheimer reaction in response to the antimicrobial therapy.

ACCESSION NUMBER: 2001:167903 USPATFULL
TITLE: Crohn's disease diagnostic and treatment methods and compositions
INVENTOR(S): Shafran, Ira, 1316 Greencove Rd., Winter Park, FL, United States 32789

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6297015	B1	20011002	
APPLICATION INFO.:	US 1999-404095		19990923	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-101579P	19980924	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED

omerase I inhibiting agent is irinotecan. When the DNA topoisomerase I inhibiting agent is irinotecan, the source of a COX-2 inhibiting agent is preferably a source of a COX-2 selective inhibiting agent, and more preferably selected from the group consisting of **celecoxib**, valdecoxib, deracoxib, rofecoxib, etoricoxib, meloxicam, and ABT-963. Alternatively, the source of a COX-2 selective inhibiting agent can be a chromene COX-2 selective inhibiting agent. In another embodiment, when the DNA topoisomerase I inhibiting agent is irinotecan, the source of a COX-2 inhibiting agent can be a prodrug of a COX-2 selective inhibiting agent, preferably parecoxib. For **treatment** or prevention of the DNA topoisomerase I inhibiting agent-related **diarrhea**, the source of a COX-2 selective inhibiting agent can be administered to the subject by essentially any convenient route. For example, the source of a COX-2 selective inhibiting agent can be administered orally, parenterally (e.g., intravenously, subcutaneously, or intramuscularly), transdermally, or rectally. The source of a COX-2 inhibiting agent and the DNA topoisomerase I inhibiting agent can be administered to the subject in essentially any convenient regimen. For example, the source of the COX-2 selective inhibiting agent can be administered to the subject before **treating** the subject with the DNA topoisomerase I inhibiting agent. Alternatively, the source of the COX-2 selective inhibiting agent can be administered to the subject concurrently with **treating** the subject with the DNA topoisomerase I inhibiting agent. In another alternative the source of the COX-2 selective inhibiting agent can be administered to the subject after **treating** the subject with the DNA topoisomerase I inhibiting agent.

ACCESSION NUMBER: 2002:192070 USPATFULL
TITLE: Antiangiogenic combination therapy for the treatment of cancer
INVENTOR(S): McKearn, John P., Wildwood, MO, UNITED STATES
Gordon, Gary B., Highland Park, IL, UNITED STATES
Cunningham, James, Chicago, IL, UNITED STATES
Gately, Stephen T., Palatine, IL, UNITED STATES
Koki, Alane T., Beaufort, MO, UNITED STATES
Masferrer, Jaime L., Ballwin, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002103141	A1	20020801
APPLICATION INFO.:	US 2001-843132	A1	20010425 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-470951, filed on 22 Dec 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113786P	19981223 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Pharmacia Corporation, Corporate Patent Department, P.O. Box 5110, Chicago, IL, 60680-9889
NUMBER OF CLAIMS: 181
EXEMPLARY CLAIM: 1

:34 ON 05 JUN 2003)

FILE 'REGISTRY' ENTERED AT 17:26:59 ON 05 JUN 2003
L1 1 S ROFECOXIB
L2 1 S CELECOXIB/CN

FILE 'CAPLUS' ENTERED AT 17:27:45 ON 05 JUN 2003
L3 383 S L1/USES
L4 1409 S (RADIATION OR RADIO?) (1S) ((SIDE OR ADVERSE OR UNDESIRED OR
L5 89355 S FATIGUE OR DIARRHEA OR (RECTAL BLEEDING) OR PROCTITIS OR SIGM
L6 22148 S DERMATITIS OR (LARGE BOWEL IRRITATION) OR (SMALL BOWEL IRRITA
L7 109277 S L5 OR L6
L8 106 S L4 AND L7
L9 1 S L3 AND L8
L10 28 S L3 AND L7
L11 17088 S (L5 (1S) TREAT?) OR (TREAT? (1S)L6)
L12 13 S L11 AND L3
L13 11975 S DERMATITIS
L14 2 S (LARGE BOWEL IRRITATION) OR (SMALL BOWEL IRRITATION) OR (BOW
L15 10189 S NAUSEA OR VOMITING
L16 1100 S (LARGE BOWEL IRRITATION) OR (SMALL BOWEL IRRITATION) OR (BOW
L17 74418 S FATIGUE
L18 13344 S DIARRHEA
L19 89355 S FATIGUE OR DIARRHEA OR (RECTAL BLEEDING) OR PROCTITIS OR SIGM
L20 53 S (RECTAL BLEEDING)
L21 54 S (RECTAL (2A) BLEEDING)
L22 57 S (RECT? (2A) BLEEDING)
L23 95 S PROCTITIS
L24 3 S SIGMOIDITIS
L25 228 S (URINARY FREQUENCY)
L26 573 S PROSTATITIS
L27 1009 S CYSTITIS
L28 1 S L27 AND L3
L29 2 S L26 AND L3
L30 0 S L25 AND L3
L31 1 S L24 AND L3
L32 0 S L23 AND L3
L33 0 S L22 AND L3
L34 0 S L21 AND L3
L35 0 S L20 AND L3
L36 8 S L19 AND L3
L37 6 S L18 AND L3
L38 2 S L17 AND L3
L39 6 S L16 AND L3
L40 7 S L15 AND L3
L41 0 S L14 AND L3
L42 16 S L13 AND L3
L43 13 S L12 AND L3
L44 13 S L11 AND L3
L45 28 S L10 AND L3
L46 472 S L2/USES
L47 13 S L10 AND L46
L48 14 S L11 AND L46
L49 9 S L12 AND L46
L50 9 S L13 AND L46
L51 0 S L14 AND L46
L52 2 S L15 AND L46
L53 6 S L16 AND L46
L54 3 S L17 AND L46
L55 8 S L18 AND L46
L56 11 S L19 AND L46
L57 0 S L20 AND L46
L58 0 S L21 AND L46
L59 0 S L22 AND L46

```
L60             0 S L23 AND L46
L61             1 S L24 AND L46
L62             0 S L25 AND L46
L63             2 S L26 AND L46
L64             1 S L27 AND L46
L65             1 S L28 AND L46
L66             2 S L29 AND L46
L67           487 S L28-L64
L68           305 S L67 AND TREAT?

=>
```

```
PATFULL' ENTERED AT 16:21:21 ON 05 JUN 2003
L1         74653 FILE CAPLUS
L2         10709 FILE PCTFULL
L3         23141 FILE USPATFULL
     TOTAL FOR ALL FILES
L4        108503 S (VITAMIN B3) OR NICOTINIC OR NICOTINAMIDE OR NICOTIN?
L5           746 FILE CAPLUS
L6           480 FILE PCTFULL
L7           898 FILE USPATFULL
     TOTAL FOR ALL FILES
L8          2124 S TREAT? (1S) PRURITUS
L9            11 FILE CAPLUS
L10           52 FILE PCTFULL
L11           89 FILE USPATFULL
     TOTAL FOR ALL FILES
L12          152 S L8 AND L4
L13          171 FILE CAPLUS
L14         1482 FILE PCTFULL
L15         1934 FILE USPATFULL
     TOTAL FOR ALL FILES
L16         3587 S (URTICARIA OR ASTHMA OR RHINITIS) AND L4
L17           89 FILE CAPLUS
L18         1240 FILE PCTFULL
L19         1491 FILE USPATFULL
     TOTAL FOR ALL FILES
L20         2820 S ((URTICARIA OR ASTHMA OR RHINITIS)(1S) TREAT?) AND L4
L21        15583 FILE CAPLUS
L22         2544 FILE PCTFULL
L23         5578 FILE USPATFULL
     TOTAL FOR ALL FILES
L24        23705 S (VITAMIN B2) OR RIBOFLAVIN
L25           15 FILE CAPLUS
L26          417 FILE PCTFULL
L27          293 FILE USPATFULL
     TOTAL FOR ALL FILES
L28          725 S ((URTICARIA OR ASTHMA OR RHINITIS)(1S) TREAT?) AND L24
L29            1 FILE CAPLUS
L30           24 FILE PCTFULL
L31           21 FILE USPATFULL
     TOTAL FOR ALL FILES
L32           46 S L8 AND L24
L33            1 FILE CAPLUS
L34            1 FILE PCTFULL
L35            0 FILE USPATFULL
     TOTAL FOR ALL FILES
L36            2 S L8 (1S) L24
L37            0 FILE CAPLUS
L38          219 FILE PCTFULL
L39          172 FILE USPATFULL
     TOTAL FOR ALL FILES
L40          391 S ((URTICARIA OR ASTHMA OR RHINITIS)(1S) TREAT?) AND L4/CLM
L41            0 FILE CAPLUS
L42           18 FILE PCTFULL
L43           11 FILE USPATFULL
     TOTAL FOR ALL FILES
L44           29 S L8 AND L4/CLM
L45            0 FILE CAPLUS
L46           85 FILE PCTFULL
L47           30 FILE USPATFULL
     TOTAL FOR ALL FILES
L48          115 S ((URTICARIA OR ASTHMA OR RHINITIS)(1S) TREAT?)/CLM AND L4/CLM
L49            0 FILE CAPLUS
L50            7 FILE PCTFULL
L51            1 FILE USPATFULL
```

```
     TOTAL FOR ALL FILES
L52             8 S L48 AND L44
L53             0 FILE CAPLUS
L54             4 FILE PCTFULL
L55             1 FILE USPATFULL
     TOTAL FOR ALL FILES
L56             5 S L8 AND L24/CLM

=> s l28 and l24/clm
'CLM' IS NOT A VALID FIELD CODE
L57             0 FILE CAPLUS
L58            29 FILE PCTFULL
L59            13 FILE USPATFULL

TOTAL FOR ALL FILES
L60            42 L28 AND L24/CLM

=> d l59 1-13 hit, ibib
```